Impact of genomic testing on urologists' treatment preference in favorable risk prostate cancer: A randomized trial

INTRODUCTION: The Oncotype Dx Genomic Prostate Score (GPS) is a 17‐gene relative expression assay that predicts adverse pathology at prostatectomy. We conducted a novel randomized controlled trial to assess the impact of GPS on urologist's treatment preference for favorable risk prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Carbunaru, Samuel, Sun, Zequn, McCall, Cordero, Ofori, Bernice, Marshall, Norma, Wang, Heidy, Abern, Michael, Liu, Li, Hollowell, Courtney M. P., Sharifi, Roohollah, Vidal, Patricia, Kajdacsy‐Balla, Andre, Sekosan, Marin, Ferrer, Karen, Wu, Shoujin, Gallegos, Marlene, Gann, Peter H., Moreira, Daniel, Sharp, Lisa K., Ferrans, Carol E., Murphy, Adam B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587942/
https://www.ncbi.nlm.nih.gov/pubmed/37787097
http://dx.doi.org/10.1002/cam4.6615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587942/
https://www.ncbi.nlm.nih.gov/pubmed/37787097
http://dx.doi.org/10.1002/cam4.6615

Ejemplares similares